Breaking Down Biologics in Atopic Dermatitis: Choosing the Right Path for Patients - Episode 9
Patient Considerations to Guide Biologic Treatment Selection in Atopic Dermatitis
Panelists discuss how selecting a biologic for atopic dermatitis involves comprehensive assessment of patient-specific factors including age (with dupilumab's broader approval for patients as young as 6 months vs other biologics approved only for those aged 12 years or older), weight (affecting dosing considerations), disease phenotype, symptom predominance (especially itch severity for nemolizumab consideration), comorbidities (including asthma, food allergies, and ocular conditions), prior treatment responses, insurance coverage, administration preferences, anticipated adherence, treatment goals, and previous biologic experience—with biologic-naive patients typically receiving broader consideration, whereas those with prior biologic exposure require careful evaluation of previous response patterns, reasons for discontinuation, and strategic selection of agents with different mechanisms to potentially overcome therapeutic plateaus.
Video content above is prompted by the following:
- What patient factors do you take into consideration when prescribing a biologic for atopic dermatitis?
- How does a patient’s age or weight impact their biologic treatment options?
- Dupilumab is approved for patients 6 months or older.
- Lebrikizumab, tralokinumab, and nemolizumab are approved for patients 12 years or older.
- Does your approach to treatment selection differ if the patient is biologic-naive vs if the patient has tried a biologic in the past?
